Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Go back to Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer| AGENUS (NASDAQ: AGEN) | Delayed: 3.07 +0.03 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.04 | 52 Week High | $7.49 | |||
| Open | $2.99 | 52 Week Low | $2.61 | |||
| Day High | $3.18 | P/E | N/A | |||
| Day Low | $2.99 | EPS | $-1.10 | |||
| Volume | 438,570 | |||||
| (NASDAQ: INKT) | Delayed: 12.33 +0.08 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.25 | 52 Week High | $ | |||
| Open | $11.88 | 52 Week Low | $ | |||
| Day High | $12.58 | P/E | N/A | |||
| Day Low | $11.88 | EPS | $ | |||
| Volume | 22,907 | |||||
